ライフサイエンスコーパス: IRIS

1 IRIS cases were similar overall to non-IRIS cases in his

2 IRIS flow cytometry data provides useful information in

3 IRIS is associated with an increased risk of hospitaliza

4 IRIS reflects pathogenic immune responses against opport

5 IRIS Registry data were extracted if the eye had a proce

6 IRIS Registry patients with nAMD who received bevacizuma

7 IRIS was independently associated with increased risk of

8 IRIS was independently associated with increased risk of

9 IRIS was then used to investigate a confiscated street s

10 The 2011 IRIS assessment of dichloromethane provides insights int

11 Among 3876 IRIS participants (mean age, 63 years; 65% male), 377 st

12 The study cohort was composed of 3876 IRIS participants, mean age 63 years, 65% male, 89% whit

13 Of the 3876 IRIS participants, 3398 had a 3MS score at baseline and

14 Plasma from 51 IRIS cases, including 6 stratified by preenrollment CD4

15 An independent review committee adjudicated IRIS events.

16 t in 2 cases JCV persisted > 21 months after IRIS accompanied by delayed clinical improvement.

17 n a decline of CD8(+) T-cell responses after IRIS.

18 ary syndromes (MI and unstable angina) among IRIS participants.

19 n CD4 cell count at lymphoma diagnosis among IRIS cases was 173 cells/microL (interquartile range, 73

20 ncreased early mortality was suggested among IRIS cases.

21 Big Data drawing on Medicare claims and IRIS Registry records can help identify additional areas

22 Medicare claims and IRIS(R) Registry data were used to calculate Medicare Pa

23 e review, analysis of IRIS Registry data and IRIS-50, a visual acuity quality measure.

24 and significantly lower rates of relapse and IRIS than itraconazole.

25 By using both approaches, IRIS can overcome with reasonable accuracy the analytica

26 ce and features of histoplasmosis-associated IRIS in a cohort of PLHIV.

27 Histoplasmosis-associated IRIS incidence was low but generated significant morbidi

28 wenty-two cases of histoplasmosis-associated IRIS were included (14 infectious/unmasking and 8 parado

29 thout a diagnosis of tuberculosis-associated IRIS (controls), on the basis of outcomes recorded in th

30 ls and patients with tuberculosis-associated IRIS (p=0.45), were substantially lower in patients who

31 uberculosis who have tuberculosis-associated IRIS and death.

32 Patients with tuberculosis-associated IRIS had reduced pre-ART concentrations of several pro-i

33 Tuberculosis-associated IRIS has been associated with quicker recovery of cellul

34 after ART initation, tuberculosis-associated IRIS was independently associated with greater increases

35 Tuberculosis-associated IRIS was uncommon (4/arm), with no discontinuations for

36 ation with death and tuberculosis-associated IRIS, compared with controls.

37 d patients as having tuberculosis-associated IRIS, early mortality, or survival without a diagnosis o

38 rall survival at 5 years was similar between IRIS (49%; 95% confidence interval [CI], 37%-64%) and no

39 ed associations between baseline biomarkers, IRIS, immune recovery at week 48, and death by week 48 w

40 te associations between baseline biomarkers, IRIS, immune recovery at week 48, and death by week 48.

41 several ovarian cancer cell lines, and BRCA1-IRIS silencing or inactivation using a novel inhibitory

42 In a mouse xenograft model, BRCA1-IRIS inactivation using this novel inhibitory peptide re

43 varian epithelial cells overexpressing BRCA1-IRIS formed metastasis in mice when injected in the peri

44 Here, we report BRCA1-IRIS-overexpressing (IRISOE) TNBC cells secrete high lev

45 ovarian cancer samples analyzed showed BRCA1-IRIS and survivin overexpression and lacked nuclear FOXO

46 We show that BRCA1-IRIS activates two autocrine signaling loops, brain-deri

47 ther, these data strongly suggest that BRCA1-IRIS and/or BDNF/TrkB and NRG1/ErbB2 could serve as rati

48 The BRCA1-IRIS oncogene promotes breast cancer aggressiveness by r

49 form tumors or metastases in mice when BRCA1-IRIS was silenced in them.

50 This study investigates whether BRCA1-IRIS is a novel treatment target for ovarian cancers and

51 relationship between antibody immunity and C-IRIS risk has not been investigated.

52 d significant inverse associations between C-IRIS and IgM (P = .0003), Lam-IgM (P = .0005), Lam-IgG (

53 There were no associations between C-IRIS and total or memory B cells.

54 IV-infected patients with CM who developed C-IRIS and 63 who did not, and evaluated associations of t

55 nificantly lower in patients who developed C-IRIS than those who did not.

56 sociated with increased risk of developing C-IRIS.

57 Patients with CM who experienced C-IRIS (N = 27) upon ART initiation were compared to CD4+

58 ecrosis factor-alpha levels were higher in C-IRIS patients compared to controls (all P < .05), with I

59 e value in furthering our understanding of C-IRIS pathogenesis and hold promise as candidate biomarke

60 nd hold promise as candidate biomarkers of C-IRIS risk.

61 , 1.96-44.0]; P = .005) were predictive of C-IRIS.

62 ociations of these parameters with risk of C-IRIS.

63 vels of cytokines and chemokines predicted C-IRIS and are potential predictive biomarkers.

64 mune reconstitution inflammatory syndrome (C-IRIS), upon initiation of antiretroviral therapy (ART).

65 mune reconstitution inflammatory syndrome (C-IRIS).

66 The immunological mechanisms underlying C-IRIS are incompletely defined and no reliable predictive

67 ls, both of which could be associated with C-IRIS immunopathogenesis.

68 CD4+ T-cell count-matched patients without C-IRIS (N = 27).

69 Here we present a tool called IRIS-EDA, which is a Shiny web server for expression dat

70 CM-IRIS was associated with an increasing frequency of CSF

71 to more effectively treat CM and prevent CM-IRIS.

72 21) of antifungal therapy, and those with CM-IRIS (n = 10).

73 he percentage of follow-up visits completed (IRIS Registry 85.6%, RCT 96.1%, P < .001) and in the pro

74 We used a consensual IRIS case definition, submitted to the agreement of 2 ex

75 baseline CD4 count <350 cells/muL developed IRIS.

76 hs of ART, 97 (19.2%) participants developed IRIS and 31 (6.5%) died.

77 nitiation, 97 (19.2%) participants developed IRIS and 31 (6.5%) died.

78 Ten patients developed IRIS (6 mycobacterial).

79 sregulated immune response, with exacerbated IRIS and greater pulmonary function deficits than those

80 were not significantly different among FBP, IRIS, and SAFIRE in paired comparisons (median Agatston

81 crosis factor blockade may be beneficial for IRIS and warrants further study in clinical trials.

82 common (4/arm), with no discontinuations for IRIS.

83 18,841 children aged 3-7 years eligible for IRIS-50, 77.3% were successful.

84 transform infrared imaging spectroscopy (FT-IRIS) was investigated.

85 The FT-IRIS method shows potential to be used as a rapid and se

86 In 3 patients with post-HCT IRIS related to mycobacterial infection, in vitro data d

87 lower hemoglobin at baseline were at higher IRIS risk (hazard ratio [HR], 1.2; P = .004).

88 processing correction significantly improved IRIS accuracy in both natural samples and alcohol diluti

89 disease burden) were significantly higher in IRIS vs non-IRIS (P = .010, .017, and .029, respectively

90 bial translocation appear to be important in IRIS pathogenesis.

91 cells and monocytes after ART initiation in IRIS/mycobacterial IRIS compared with non-IRIS patients.

92 roaches to cope with contaminated samples in IRIS: on-line oxidation of organic compounds (MCM) and p

93 neic mouse models, silencing or inactivating IRIS in TNBC cells lowered the levels of circulating GM-

94 and Respiratory Syncytial Virus in Infants (IRIS) study was a prospective observational study done a

95 These changes provide insight into IRIS pathogenesis and could be exploited to more effecti

96 g exchangeable single-molecule localization (IRIS) approach to SMLM, in the context of the fibrous ac

97 s met a uniformly applied unmasking lymphoma IRIS case definition.

98 pleen FDG uptake was higher in mycobacterial IRIS specifically.

99 s after ART initiation in IRIS/mycobacterial IRIS compared with non-IRIS patients.

100 way is not only a biomarker of mycobacterial IRIS but also a major mediator of pathology distinct fro

101 metabolism is associated with mycobacterial IRIS, HIV viremia, and Glut-1 expression on CD4+ cells a

102 erse events in 3 patients with mycobacterial IRIS.

103 ls/muL, were analyzed and compared to 94 non-IRIS controls.

104 % confidence interval [CI], 37%-64%) and non-IRIS (44%; 95% CI, 39%-50%), although increased early mo

105 Cs from paradoxical TB-IRIS patients and non-IRIS controls (HIV-TB-coinfected patients commencing ant

106 rapy, iNKT cells in TB-IRIS patients and non-IRIS controls were compared longitudinally.

107 nitiation could distinguish TB-IRIS from non-IRIS individuals.

108 ion, BM and spleen mean SUV decreased in non-IRIS (P = .004, .013) but not IRIS subjects.

109 tected in patients with TBM-IRIS than in non-IRIS controls.

110 ix metalloproteinases, compared with TBM-non-IRIS.

111 IRIS cases were similar overall to non-IRIS cases in histologic distribution and clinical chara

112 Patients with TB-IRIS were compared to non-IRIS controls using chi(2) and rank-sum tests and logist

113 en) were significantly higher in IRIS vs non-IRIS (P = .010, .017, and .029, respectively) and signif

114 in IRIS/mycobacterial IRIS compared with non-IRIS patients.

115 ses to hkH37Rv in TB-IRIS, compared with non-IRIS PBMC (p = 0.035).

116 creased in non-IRIS (P = .004, .013) but not IRIS subjects.

117 MDA and MDMA, we demonstrate the ability of IRIS to distinguish closely related NPS.

118 Literature review, analysis of IRIS Registry data and IRIS-50, a visual acuity quality

119 We identified a cohort of IRIS Registry eyes (2013-2017) that received either a gl

120 n CSF tend to evolve with the development of IRIS, with increasing proportions of activated CD4(+) T

121 To investigate the clinical impact of IRIS in adults with HIV and CD4 counts below 100 cells/u

122 We investigated the clinical impact of IRIS in PLWH and CD4 counts <100 cells/muL starting ART

123 The incidence of IRIS, and drug toxicity was not significantly different

124 meaningful protection from the occurrence of IRIS in people with advanced HIV infection.

125 meaningful protection from the occurrence of IRIS in persons with advanced HIV infection.

126 tified hemoglobin <8.5 g/dL as predictive of IRIS and C-reactive protein (CRP) >106 mug/mL and BMI <1

127 n less than 8.5 g/dL as highly predictive of IRIS and CRP>106 ug/ml and BMI < 15.6 kg/m2 as predictiv

128 evels may be clinically useful predictors of IRIS and death risk.

129 dimer may be clinically useful predictors of IRIS and death risk.

130 data including seizure history, presence of IRIS, and MR imaging scans from PML patients evaluated a

131 collected from electronic health records of IRIS(R) Registry participating ophthalmology practices.

132 globin at study start were at higher risk of IRIS (HR 1.2, p=0.004).

133 -alpha2 were associated with greater risk of IRIS.

134 blockade with maraviroc reduces the risk of IRIS.

135 ant effect on frequency, time or severity of IRIS events after ART initiation.

136 ariance ANOVA to investigate their impact on IRIS duration; and (3) a linear mixed model to assess th

137 azard ratio [HR] = 1.05; p = 0.92), but once IRIS emerged, its duration was significantly longer in p

138 des in the American Academy of Ophthalmology IRIS (Intelligent Research in Sight) Registry database,

139 need heightened awareness for new onset PML, IRIS, and MS relapse in evaluating neurological decline

140 tics of inflammatory NTZ-PML lesions and PML-IRIS to determine differentiating and overlapping featur

141 earliest sign of natalizumab-associated PML-IRIS with a frequent imaging pattern of contrast-enhanci

142 inflammation (90% at diagnosis, 100% at PML-IRIS).

143 nosis was similar to the pattern seen at PML-IRIS, with contrast enhancement representing the most fr

144 o investigate their impact on full-blown PML-IRIS latency; (2) an analysis of variance ANOVA to inves

145 r prophylactic use to prevent full-blown PML-IRIS seems to negatively impact on the longitudinal disa

146 ML presenting with lesions suggestive of PML-IRIS during follow-up.

147 the earliest imaging characteristics of PML-IRIS manifestation in natalizumab-treated patients with

148 e most common imaging sign suggestive of PML-IRIS, seen in 92.3% of the patients (with patchy and/or

149 were followed up until the occurrence of PML-IRIS.

150 ne reconstitution inflammatory syndrome (PML-IRIS).

151 ne reconstitution inflammatory syndrome (PML-IRIS).

152 (10%) at diagnosis, as compared with the PML-IRIS stage (40%).

153 at the time of PML diagnosis and at the PML-IRIS stage overlap but differ in their severity of infla

154 reatment with PLEX was not associated to PML-IRIS latency (hazard ratio [HR] = 1.05; p = 0.92), but o

155 nger BPI use, after accounting for potential IRIS and other factors.

156 , and enhances the resolution of PcP-related IRIS.

157 ffectively cleared Pneumocystis and resolved IRIS.

158 g in the American Academy of Ophthalmology's IRIS (Intelligent Research in Sight) Registry.

159 ometry data (Immune Response In Scleroderma, IRIS) from consented patients followed at the Johns Hopk

160 tients in the Intelligent Research in Sight (IRIS) Registry, 2013-2018.

161 lmology (AAO) Intelligent Research in Sight (IRIS) Registry.

162 These capabilities improve the existing SP-IRIS technology, resulting in a more robust and versatil

163 tomatitis virus (VSV) as a model virus on SP-IRIS platform.

164 terferometric Reflectance Imaging Sensor (SP-IRIS) that allows multiplexed phenotyping and digital co

165 terferometric reflectance imaging sensor (SP-IRIS), a simple, label-free biosensor capable of imaging

166 P), iterative reconstruction in image space (IRIS), and sinogram-affirmed iterative reconstruction (S

167 y the Interface Region Imaging Spectrograph (IRIS) reveal that it is difficult to determine what is u

168 ) or an isotope ratio infrared spectrometer (IRIS) (in this case a Delta Ray (Thermo Fisher Scientifi

169 Isotope-ratio infrared spectroscopy (IRIS) offers a cheaper alternative to isotope-ratio mass

170 Infrared ion spectroscopy (IRIS), a mass-spectrometry-based technique exploiting re

171 nsulin Resistance Intervention after Stroke (IRIS) trial, patients with a recent ischaemic stroke or

172 tive Influenza Resistance Information Study (IRIS; NCT00884117) were analyzed by polymerase chain rea

173 immune reconstitution inflammatory syndrome (IRIS) after initiation of antiretroviral therapy at the

174 immune reconstitution inflammatory syndrome (IRIS) after successful initiation of ART.

175 immune reconstitution inflammatory syndrome (IRIS) and death at antiretroviral therapy (ART) initiati

176 immune reconstitution inflammatory syndrome (IRIS) and death soon after initiation of antiretroviral

177 immune reconstitution inflammatory syndrome (IRIS) and death.

178 immune reconstitution inflammatory syndrome (IRIS) following engraftment.

179 Immune reconstitution inflammatory syndrome (IRIS) in human immunodeficiency virus (HIV)-infected per

180 immune reconstitution inflammatory syndrome (IRIS) in natalizumab-associated progressive multifocal l

181 immune reconstitution inflammatory syndrome (IRIS) in people living with human immunodeficiency virus

182 Immune reconstitution inflammatory syndrome (IRIS) is a major adverse event of antiretroviral therapy

183 immune reconstitution inflammatory syndrome (IRIS) is currently unclear.

184 Immune reconstitution inflammatory syndrome (IRIS) occurs in up to 40% of individuals co-infected wit

185 Immune reconstitution inflammatory syndrome (IRIS) represents an unexpected inflammatory response sho

186 immune reconstitution inflammatory syndrome (IRIS), and the side-effect profile.

187 immune reconstitution inflammatory syndrome (IRIS), but in 2 cases JCV persisted > 21 months after IR

188 immune reconstitution inflammatory syndrome (IRIS), but its underlying cause remains poorly understoo

189 immune reconstitution inflammatory syndrome (IRIS).

190 of an immune recovery inflammatory syndrome (IRIS).

191 immune reconstitution inflammatory syndrome (IRIS).

192 immune reconstitution inflammatory syndrome (IRIS).

193 immune reconstitution inflammatory syndrome (IRIS).

194 immune reconstitution inflammatory syndrome (IRIS).

195 via the Intelligent Retinal Imaging System (IRIS) from June 2013 to April 2014 were included.

196 EPA's Integrated Risk Information System (IRIS) completed an updated toxicological review of dichl

197 om EPA's Integrated Risk Information System (IRIS) database, Spearman rank correlation identified 68%

198 t of the Integrated Risk Information System (IRIS), the U.S. Environmental Protection Agency (EPA) ha

199 he EPA's Integrated Risk Information System (IRIS).

200 TB-IRIS patients also exhibited greater upregulation of NLR

201 TB-IRIS patients and controls had similar CD4 counts, level

202 In contrast, TB-IRIS patients had significantly greater early increases

203 ntiretroviral therapy who did not develop TB-IRIS).

204 ts without TB, and patients who developed TB-IRIS exhibited the greatest increase in casp1 expression

205 RT initiation only in those who developed TB-IRIS.

206 -6 after ART initiation could distinguish TB-IRIS from non-IRIS individuals.

207 Phenotypic changes in T-cells during TB-IRIS and their relationship with systemic inflammation a

208 ated with TB-IRIS, both before and during TB-IRIS onset.

209 d patients is increased before and during TB-IRIS, informing novel diagnostic strategies.

210 some activation, was also elevated during TB-IRIS.

211 No biomarkers for TB-IRIS have been identified and the underlying mechanisms

212 granzyme B secretion reduced in PBMC from TB-IRIS patients during corticosteroid treatment.

213 y, suggesting a role for lung function in TB-IRIS definitions.

214 nflammasome activation, are implicated in TB-IRIS pathogenesis.

215 plicate the granule exocytosis pathway in TB-IRIS pathophysiology.

216 +)Valpha24(+)) proportions were higher in TB-IRIS patients (p = 0.004) and were a source of perforin.

217 n and T-cell subsets also were similar in TB-IRIS patients and controls.

218 ing antiretroviral therapy, iNKT cells in TB-IRIS patients and non-IRIS controls were compared longit

219 els were lower both pre- and post-cART in TB-IRIS patients, providing evidence of inadequate inflamma

220 CD4(+) T cells and NK cells was higher in TB-IRIS patients, providing evidence that IL-18 is a marker

221 ome activation both pre- and post-cART in TB-IRIS patients.

222 secretion of cytokines including IL-1 in TB-IRIS patients.

223 al expansion of CXCR3(+) CCR6(-) cells in TB-IRIS patients.

224 iNKT cells in TB-IRIS were CD4+CD8- subset depleted and degranulated arou

225 creased IFN-gamma responses to hkH37Rv in TB-IRIS, compared with non-IRIS PBMC (p = 0.035).

226 cytokines and caspase-1/5 are elevated in TB-IRIS.

227 erence 3.587 and 2.828, respectively), in TB-IRIS.

228 ells may contribute to immunopathology in TB-IRIS.

229 ociated with a 2.8-fold increased risk of TB-IRIS (95% confidence interval, 1.1 to 7.5-fold).

230 ta provide insight on the pathogenesis of TB-IRIS and may assist the development of specific therapie

231 ive TB was associated with development of TB-IRIS following antiretroviral therapy initiation.

232 At the characteristic time of TB-IRIS onset (week 2), the signature is characterized by o

233 leted and degranulated around the time of TB-IRIS onset.

234 was associated with a higher incidence of TB-IRIS than delayed ART (RR, 2.31 [CI, 1.87 to 2.86]; I2 =

235 strategy for prevention and treatment of TB-IRIS.

236 ociated with a 2-fold higher frequency of TB-IRIS.

237 responses and development of paradoxical TB-IRIS on antiretroviral therapy (ART).

238 analyses of human PBMCs from paradoxical TB-IRIS patients and non-IRIS controls (HIV-TB-coinfected p

239 ssociated with development of paradoxical TB-IRIS.

240 une reconstitution inflammatory syndrome (TB-IRIS) complicates combination antiretroviral therapy (cA

241 une reconstitution inflammatory syndrome (TB-IRIS) frequently complicates combined antiretroviral the

242 une reconstitution inflammatory syndrome (TB-IRIS) remains unclear.

243 une reconstitution inflammatory syndrome (TB-IRIS) when they commence antiretroviral therapy.

244 une reconstitution inflammatory syndrome (TB-IRIS), in Cape Town, South Africa.

245 une reconstitution inflammatory syndrome (TB-IRIS).

246 une reconstitution inflammatory syndrome (TB-IRIS).

247 une reconstitution inflammatory syndrome (TB-IRIS).

248 asma mitochondrial DNA levels showed that TB-IRIS patients experienced greater cell death, especially

249 ory cytokines in patients who progress to TB-IRIS.

250 immunopathological mechanisms underlying TB-IRIS are incompletely defined, and improved understandin

251 In a secondary analysis, patients with TB-IRIS had rapid, concomitant increases in tuberculosis-sp

252 Patients with TB-IRIS were compared to non-IRIS controls using chi(2) and

253 lular matrix turnover was associated with TB-IRIS, both before and during TB-IRIS onset.

254 enced, which is greatest in patients with TB-IRIS.

255 innate immune dysfunction associated with TB-IRIS.

256 ry response that manifests clinically as TBM-IRIS in most, but not all, patients with TBM.

257 gnosis and 2 weeks after ART initiation, TBM-IRIS was associated with severe, compartmentalized infla

258 transcripts, from before development of TBM-IRIS through IRIS symptom onset.

259 To investigate the pathogenesis of TBM-IRIS, we performed longitudinal whole-blood microarray a

260 ate immune system in the pathogenesis of TBM-IRIS.

261 Patients in whom TBM-IRIS eventually developed had significantly more abundan

262 lammasomes was detected in patients with TBM-IRIS than in non-IRIS controls.

263 We hypothesized that IRIS is associated with increased glycolysis and that 18

264 The IRIS algorithm population statistics were calculated.

265 The IRIS algorithm shows promise as a screening program, but

266 The IRIS Registry cohort included 419 eyes: 183 (43.7%) trab

267 The IRIS Registry identified 1,760,066 individuals with ambl

268 The IRIS trial (Insulin Resistance Intervention after Stroke

269 The IRIS trial (Insulin Resistance Intervention after Stroke

270 The IRIS-based interpretations were compared with manual int

271 sight-threatening diabetic eye disease, the IRIS algorithm positive predictive value was 10.8% (95%

272 RNA at lymphoma diagnosis resulting from the IRIS case definition.

273 Relating data from the IRIS Registry and NHANES could be a novel method for ass

274 Data from the IRIS Registry were analyzed for patients who underwent v

275 Data from the IRIS Registry were used to calculate the real-world prev

276 We analyzed data from the IRIS Registry, from January 1, 2012 to December 31, 2014

277 Innovations in the IRIS assessment include estimation of cancer risk specif

278 1 year; and compared treatment groups in the IRIS Registry cohort and this cohort to the TVT RCT coho

279 ovement, such as in the 18.3% of eyes in the IRIS Registry having 1-month-postoperative VA worse than

280 Visual acuity (VA) in the IRIS Registry in eyes with and without postoperative end

281 In the IRIS Registry the endophthalmitis rate after cataract su

282 In the IRIS Registry, eyes undergoing vitrectomy for vitreous o

283 yes for the cohort were not available in the IRIS Registry.

284 Big data from clinical registries like the IRIS Registry has great potential for evaluating rare co

285 The sensitivity of the IRIS algorithm in detecting sight-threatening diabetic e

286 Sensitivity and false-negative rate of the IRIS computer-based algorithm compared with reading cent

287 In the case of the IRIS system, we demonstrate that the use of two standard

288 In this large urban setting, the IRIS computer algorithm-based screening program had a hi

289 from before development of TBM-IRIS through IRIS symptom onset.

290 It is noteworthy that, for the first time, IRIS-EDA provides a framework to expedite submission of

291 ng proST versus therST was not associated to IRIS latency (HR = 0.67; p = 0.39) or duration (p = 0.95

292 There was no difference in the time to IRIS events between treatment arms (HR 1.08, 95% CI (0.6

293 Median time to IRIS was 11 days (interquartile range 7-40 days) after a

294 also significant differences between the TVT IRIS Registry cohort and the TVT RCT cohort in the perce

295 The TVT IRIS Registry cohort had several significant treatment g

296 Follow-up in the TVT IRIS Registry cohort was inferior to that of the TVT RCT

297 bability of having a 1-year follow-up visit (IRIS Registry 81.4%, RCT 89.2%, P = .011).

298 ed CENTRAL, CINAHL, Embase, MEDLINE, and WHO IRIS databases for publications between Jan 1, 2000, and

299 T prior to ART initiation is associated with IRIS development and correlates with inflammatory biomar

300 D4(+) T cell subsets tightly associated with IRIS, which may serve as targets for prophylactic and/or